Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Watson Wins EU Approval to Buy Generic-Drug Maker Actavis

Oct. 5 (Bloomberg) -- Watson Pharmaceuticals Inc., maker of the generic version of Lipitor cholesterol pills, won European Union approval to buy closely held drugmaker Actavis Group hf to create the third-largest global generic-drug maker.

The European Commission said the combined company would continue to face competition from a sufficient number of credible and strong rivals, according to an e-mailed statement today.

Parsippany, New Jersey-based Watson agreed in April to buy Actavis for 4.25 billion euros ($5.6 billion), expanding its reach in Europe and Asia.

To contact the reporter on this story: Aoife White in Brussels at

To contact the editor responsible for this story: Anthony Aarons at

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.